Numinus Wellness Inc.(NUMI)
(NUMI)
Q2
13 dage siden‧25 min
Ordredybde
Lukket
Antal
Køb
0
Sælg
Antal
0
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| - | - | - | - |
Volumenvægtet gennemsnitspris
-VWAP
-Omsætning (CAD)
2.830Mæglerstatistik
Ingen data fundet
Corporate Actions
| Næste begivenhed | |
|---|---|
Finanskalender er ikke tilgængelig | |
| Tidligere begivenheder | ||
|---|---|---|
| 2024 Q2 | 15. apr. | |
| 2024 Q1 | 15. jan. | |
| 2023 Q4 | 29. nov. 2023 | |
| 2023 Q3 | 17. jul. 2023 | |
| 2023 Q2 | 13. apr. 2023 |
Data hentes fra Quartr
Nyheder og Analyser
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Q2
13 dage siden‧25 min
Nyheder og Analyser
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Corporate Actions
| Næste begivenhed | |
|---|---|
Finanskalender er ikke tilgængelig | |
| Tidligere begivenheder | ||
|---|---|---|
| 2024 Q2 | 15. apr. | |
| 2024 Q1 | 15. jan. | |
| 2023 Q4 | 29. nov. 2023 | |
| 2023 Q3 | 17. jul. 2023 | |
| 2023 Q2 | 13. apr. 2023 |
Data hentes fra Quartr
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
8. nov. 20238. nov. 2023623 registrerte eiere på Nordnet.. imponerende, jeg trodde det bare var jeg som følger sånne sære aksjer😊 er ellers i cmps, cybin og atai. Hva tror dere om numinus fremover?28. nov. 202328. nov. 2023Compass should be releasing phase 2 trial results for psilocybin vs PTSD by the end of the year, and some phase 3 data in summer 2024, so that could be interesting. Atai has data from a study on CIAS treatment using their RL-007 compounds coming in 2H of 2024. I would guess that is a significantly smaller patient demographic and I don't know anything about RL-007, but it's something. Numinus will hold an annual results conference call tomorrow. I don't think they have any new products coming out any time soon, but then again I haven't been following for a long time.
Numinus Wellness positioned to benefit from multi-billion psychedelic industry ... "Water Tower Research highlighted the recently completed acquisition of Novamind as being transformative for Numinus both strategically and financially establishing its first footprint in the US with eight wellness clinics. Novamind also quintuples Numinus’ run-rate revenue base to around C$16 million, making it one of the largest revenue generators in the psychedelic space and the broker projected that revenues could expand at a compound average growth rate of 116% over the next three years to around C$70mln. Novamind will also improve the group’s gross margins and this will accelerate the path to profitability for Numinus which the broker now expects to be achieved by 2025. Together with the Novamind acquisition the key drivers to profitability according to the broker are revenue acceleration from the expansion of Numinus’ wellness clinic network from the current 13 to 35 by the end of full-year 2025; expansion of higher-margin product offerings which could drive gross margins from the mid-20% range currently to the low 40% range; and operating leverage efficiencies because of scaling up. Buttressed by a strong balance sheet, with more than C$40mln and no debt, Water Tower Research said Numinus is well positioned to continue to expand its clinic network across North America where the regulatory barriers to psychedelics for therapeutic purposes are slowly being dismantled." https://www.proactiveinvestors.co.uk/companies/news/994069/numinus-wellness-positioned-to-benefit-from-multi-billion-psychedelic-industry-analysts-say-994069.html
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product https://ca.finance.yahoo.com/news/numinus-submits-clinical-trial-application-130000757.html
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Q2
13 dage siden‧25 min
Nyheder og Analyser
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
- 8. nov. 20238. nov. 2023623 registrerte eiere på Nordnet.. imponerende, jeg trodde det bare var jeg som følger sånne sære aksjer😊 er ellers i cmps, cybin og atai. Hva tror dere om numinus fremover?28. nov. 202328. nov. 2023Compass should be releasing phase 2 trial results for psilocybin vs PTSD by the end of the year, and some phase 3 data in summer 2024, so that could be interesting. Atai has data from a study on CIAS treatment using their RL-007 compounds coming in 2H of 2024. I would guess that is a significantly smaller patient demographic and I don't know anything about RL-007, but it's something. Numinus will hold an annual results conference call tomorrow. I don't think they have any new products coming out any time soon, but then again I haven't been following for a long time.
- Numinus Wellness positioned to benefit from multi-billion psychedelic industry ... "Water Tower Research highlighted the recently completed acquisition of Novamind as being transformative for Numinus both strategically and financially establishing its first footprint in the US with eight wellness clinics. Novamind also quintuples Numinus’ run-rate revenue base to around C$16 million, making it one of the largest revenue generators in the psychedelic space and the broker projected that revenues could expand at a compound average growth rate of 116% over the next three years to around C$70mln. Novamind will also improve the group’s gross margins and this will accelerate the path to profitability for Numinus which the broker now expects to be achieved by 2025. Together with the Novamind acquisition the key drivers to profitability according to the broker are revenue acceleration from the expansion of Numinus’ wellness clinic network from the current 13 to 35 by the end of full-year 2025; expansion of higher-margin product offerings which could drive gross margins from the mid-20% range currently to the low 40% range; and operating leverage efficiencies because of scaling up. Buttressed by a strong balance sheet, with more than C$40mln and no debt, Water Tower Research said Numinus is well positioned to continue to expand its clinic network across North America where the regulatory barriers to psychedelics for therapeutic purposes are slowly being dismantled." https://www.proactiveinvestors.co.uk/companies/news/994069/numinus-wellness-positioned-to-benefit-from-multi-billion-psychedelic-industry-analysts-say-994069.html
- Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product https://ca.finance.yahoo.com/news/numinus-submits-clinical-trial-application-130000757.html
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Lukket
Antal
Køb
0
Sælg
Antal
0
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| - | - | - | - |
Volumenvægtet gennemsnitspris
-VWAP
-Omsætning (CAD)
2.830Mæglerstatistik
Ingen data fundet
Corporate Actions
| Næste begivenhed | |
|---|---|
Finanskalender er ikke tilgængelig | |
| Tidligere begivenheder | ||
|---|---|---|
| 2024 Q2 | 15. apr. | |
| 2024 Q1 | 15. jan. | |
| 2023 Q4 | 29. nov. 2023 | |
| 2023 Q3 | 17. jul. 2023 | |
| 2023 Q2 | 13. apr. 2023 |
Data hentes fra Quartr